

Novavax to Participate in the FBR New Prescriptions Conference

April 13, 2016

GAITHERSBURG, Md., April 13, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the FBR Healthcare Series Conference New Prescriptions: Innovation in the Treatment of Diseases and Infections.

Conference details are as follows:

Date: Wednesday, April 20, 2016

Time: 9:30 a.m. U.S. Eastern Time

Location: J.W. Marriott Essex House, New York City

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.

Contact: Novavax, Inc. Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
ir@novavax.com
240-268-2000

Russo Partners, LLC David Schull Todd Davenport, Ph.D.

david.schull@russopartnersllc.com todd.davenport@russopartnersllc.com
212-845-4271